Valuation: Vericel Corporation

Market Cap 1.96B 1.69B 1.6B 1.45B 2.72B 188B 2.74B 19.02B 7.32B 95.42B 7.37B 7.21B 302B P/E 2026 *
69.4x
P/E 2027 * 43.6x
Enterprise Value 1.96B 1.69B 1.6B 1.45B 2.72B 188B 2.74B 19.02B 7.32B 95.42B 7.37B 7.21B 302B EV / Sales 2026 *
5.84x
EV / Sales 2027 * 5x
Free-Float
98.81%
Yield 2026 *
-
Yield 2027 * -
1 day+1.12%
1 week-0.61%
Current month-2.66%
1 month-12.13%
3 months+1.44%
6 months+20.28%
Current year+7.86%
1 week 37.35
Extreme 37.35
39.72
1 month 37.35
Extreme 37.35
46.01
Current year 28.95
Extreme 28.95
49.32
1 year 28.95
Extreme 28.95
49.32
3 years 28.95
Extreme 28.95
63
5 years 17.3
Extreme 17.3
63
10 years 2
Extreme 2
68.94
Manager TitleAgeSince
Chief Executive Officer 62 01/03/2013
Director of Finance/CFO 51 25/01/2021
Chief Tech/Sci/R&D Officer - 01/01/2024
Director TitleAgeSince
Director/Board Member 71 28/09/2005
Chairman 75 05/10/2012
Director/Board Member 57 23/08/2013
Date Insider Type Main position Quantity % Market Cap. Importance
8/12/26 A Exercice

Director

21,000 0.0411%
8/3/26 A Exercice

Chief Operating Officer

30,000 0.0587%
7/30/26 A Exercice

Controller/Auditor

13,500 0.0264%
Change 5-day change 1-year change 3-year change Capi.($)
+1.12%-0.61%+23.62%+8.80% 1.96B
+0.67%-2.99%+37.28%-5.56% 78.04B
-0.45%+1.23%+494.89%+25.93% 57.48B
+2.68%-1.68%-17.44%-36.27% 57.4B
+0.35%-1.87%-11.03%+27.74% 48.81B
+2.09%-0.10%+2.24%+154.85% 45.5B
-0.51%+2.04%+51.30%-15.40% 32.08B
+0.51%-1.70%+47.09%+92.64% 24.62B
+3.53%-5.42%-1.02%+170.53% 20.77B
+2.05%-0.67%+63.74%+99.55% 15.75B
Average +1.16%-3.74%+69.07%+52.28% 38.24B
Weighted average by Cap. +0.97%-3.45%+88.26%+37.36%

Financials

2026 *2027 *
Net sales 336M 290M 274M 249M 466M 32.12B 469M 3.26B 1.25B 16.34B 1.26B 1.24B 51.64B 393M 339M 321M 291M 545M 37.54B 548M 3.81B 1.46B 19.1B 1.48B 1.44B 60.34B
Net income 29.29M 25.24M 23.89M 21.66M 40.63M 2.8B 40.84M 284M 109M 1.42B 110M 108M 4.5B 47.29M 40.74M 38.58M 34.97M 65.6M 4.52B 65.93M 458M 176M 2.3B 178M 174M 7.26B
Net Debt - -
Logo Vericel Corporation
Vericel Corporation is a provider of advanced therapies for sports medicine and severe burn care markets. It has a differentiated portfolio of cell therapy and specialty biologic products. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.
Employees
398
Date Price Change Volume
14/09/26 $38.84 +1.30% 79,085
11/09/26 $38.34 +1.24% 503,531
10/09/26 $37.87 -2.87% 340,237
09/09/26 $38.99 -0.23% 366,515
08/09/26 $39.08 -2.76% 410,295
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
38.34USD
Average target price
60.57USD
Spread / Average Target
+57.98%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VCEL Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!